Pazopanib Is Not Inferior to Doxorubicin in First-Line Treatment of Elderly Patients With STS
Findings from the EPAZ study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1643 results
Selpercatinib Shows Durable Efficacy in RET-Altered Thyroid Cancer
Results from the LIBRETTO-001 study
Selpercatinib Shows Durable Efficacy in RET Fusion–positive NSCLC
Restults from the LIBRETTO-001 study in RET fusion-positive non-small cell lung cancer
Male Patients with Cancer at Higher Risk of Severe Disease Course and Mortality Attributable to COVID-19
Findings from a systematic review and meta-analysis
A Peripheral Immune Signature of Responsiveness to PD-1 Blockade in cHL
Findings from the CheckMate 205 study
FDA Approves Carfilzomib and Daratumumab with Dexamethasone for Multiple Myeloma
The efficacy was evaluated in CANDOR and EQUULEUS trials
Talazoparib Does Not Prolong OS in BRCA1/2-mutated, HER2-negative Advanced Breast Cancer
Final overall survival results from the EMBRACA trial
Outcomes of Cancer Patients with SARS-CoV-2 Infection in Veneto
Findings from a large regional analysis of population that examined the prevalence of cancer and clinical outcomes of viral infection
Population Mortality from NSCLC in the US Fell Sharply Due to Treatment Advances
Evaluation of population level mortality trends attributed to specific subtypes of lung cancer
Combination of Azacitidine and Venetoclax in Previously Untreated AML
The findings from the VIALE-A study
Strict Safety Measures in Austria Results in Low SARS-CoV-2 Detection Rate in Cancer Patients
Findings from a large testing study conducted at a tertiary care hospital in Vienna
FDA Granted Accelerated Approval to Belantamab Mafodotin-blmf for Multiple Myeloma
It was evaluated in DREAMM-2 study